Drug Profile
RBC CD4
Latest Information Update: 26 Feb 2008
Price :
$50
*
At a glance
- Originator Sheffield Pharmaceuticals
- Class Antivirals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 07 Sep 2000 Sheffield Pharmaceuticals has outlicensed the rights to RBC CD4 and is no longer involved in its development
- 21 Oct 1999 No-Development-Reported for HIV infections treatment in USA (Unknown route)
- 27 May 1997 Phase-II clinical trials for HIV infections treatment in USA (Unknown route)